Carvana Co vs Illumina, Inc. — how do they compare? Carvana Co trades at $63.83 (market cap $69.55B), while Illumina, Inc. trades at $273.58 (market cap $39.95B). The key difference: Carvana Co is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Illumina, Inc. for 83 Days on average.
| CVNA | ILMN | |
|---|---|---|
Market Cap | $69.55B | $39.95B |
Volume | 7,671,750 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $293.69 |
52-Week Low | $56.27 | $91.00 |
Typical Hold Time | 28 Days | 83 Days |
Enterprise Value | $72.04B | $41.31B |
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% with bearish technical signals but strong fundamental momentum. The stock shows impressive revenue growth from $13.7B in 2024 to $20.3B in 2025, with net income surging to $1.4B. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding the $0.39 forecast. Analyst sentiment remains divided with a $84.07 consensus target, though technical indicators show selling pressure with bearish moving averages and key resistance at $64.
Carvana presents a compelling growth story with expanding profitability and operational efficiency, though high valuation multiples and significant debt levels warrant caution. The company's aggressive capacity expansion addresses demand constraints, positioning it for continued market share gains in online auto retail. However, competitive pressures and macroeconomic sensitivity to interest rates remain key risks for investors.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →